11:45 INTRODUCTION AND WELCOME
Ron Petersen, USA
11:50 FORGETTING BUT NOT FORGOTTEN
Peter Dal-Bianco, Austria
CASE PRESENTATION PART # 1
12:00 CURRENT RESEARCH IN ACTION: COGNITIVE ASSESSMENTS
Lutz Frölich, Germany
CASE PRESENTATION: PART #2
12:30 CURRENT RESEARCH IN ACTION: IMAGING AND BIOMARKERS
Chris Rowe, Australia
CASE PRESENTATION: PART #3
12:55 CURRENT RESEARCH IN ACTION: PATIENT MANAGEMENT
José-Luis Molinuevo, Spain
13:20 PANEL DISCUSSION
13:30 SUMMARY AND CLOSE
Ron Petersen, USA
17:15 – 19:15
Hall B
SAFINAMIDE: A NEW THERAPEUTIC OPTION FOR PD PATIENTS NOT STABILISED ON LEVODOPA
Symposium Organized by: ZAMBON
CHAIR: Werner Poewe, Austria
17:15 INTRODUCTION AND WELCOME
Werner Poewe, Austria
17:20 LEVODOPA: THE MAINSTAY FOR MANAGING MOTOR SYMPTOMS
Angelo Antonini, Italy
17:45 UPDATE ON PD PATHOPHYSIOLOGY – NON-DOPAMINE PATHWAYS AS THERAPEUTIC TARGETS
Susan Fox, Canada
18:10 SAFINAMIDE – A UNIQUE TREATMENT TARGETING BOTH DOPAMINERGIC AND NON-DOPAMINERGIC SYSTEMS
Paolo Barone, Italy
18:35 QUESTION & ANSWERS SESSION
19:25 – 21:25
Hall A
TARGETING
BACE INHIBITION IN EARLY ALZHEIMER'S DISEASE
Symposium Organized by: EISAI
CHAIR: Jeffrey Cummings, USA
19:25 AMYLOID AND ALZHEIMER'S: DECREASING RISK AND INCREASING SUCCESS
Jeffrey Cummings, USA
19:45 BACE INHIBITION: THE SCIENCE AND THE STUDIES
Howard Feldman, USA
20:05 THE IMPORTANCE OF EARLY TREATMENT
Stephen Salloway, USA
20:25 SUMMARY
Jeffrey Cummings, USA
20:45 PANEL DISCUSSION Q&A
Friday, March 31, 2017
09:15 – 11:15
Hall A
TAKING THE DIRECT PATH: THE CASE FOR D1 AGONISM IN PARKINSON'S DISEASE
Symposium Organized by: PFIZER INC
CHAIR: Olivier Rascol, France
9:15 INTRODUCTION AND OPENING REMARKS
Olivier Rascol, France
9:25 PHARMACOLOGY OF DOPAMINE RECEPTORS
Richard Mailman, USA
9:55 DEVELOPMENT AND CHARACTERIZATION OF A NOVEL FAMILY OF D1/5 RECEPTOR LIGANDS
David Gray, USA
10:25 RATIONALE FOR TARGETING D1/5 RECEPTORS IN PARKINSON'S DISEASE
Erwan Bezard, France
10:55 PANEL DISCUSSION AND Q/A
11:45 – 13:25
Hall A
EXTENDING THE AMYLOID CASCADE: REASONS TO STILL BELIEVE
Symposium Organized by: ROCHE
CHAIR: Philip Scheltens, The Netherlands
11:45 WELCOME AND INTRODUCTION
Philip Scheltens, The Netherlands
11:50 IS THE AMYLOID CASCADE HYPOTHESIS STILL VALID AS A TARGET FOR DRUG THERAPY?
Dennis Selkoe, USA
12:00 THE AMYLOID-TAU RELATIONSHIP: DO WE KNOW ENOUGH TO IMPACT THE TREATMENT TARGETS?
Brad Hyman, USA
12:10 TREM2 AND MICROGLIAL ACTIVITY – NOVEL THERAPEUTIC TARGETS IN THE AMYLOID CASCADE?
Christian Haass, Germany
12:20 THE EMERGING TREATMENT PARADIGM: HOW DOES RECENT PHASE 3 CLINICAL TRIAL DATA IMPACT THE FIELD?
Philip Scheltens, The Netherlands
12:30 PANEL DEBATE / DISCUSSION
12:55 GENERAL Q & A
17:15 – 19:15
Hall B
BEYOND THE BASAL GANGLIA: ALPHA-SYNUCLEIN PATHOLOGY AND NON-MOTOR MANIFESTATIONS IN PARKINSON'S DISEASE
Symposium Organized by: PROTHENA and ROCHE
MODERATOR:
Wolfgang Oertel, Germany
17:15 WELCOME AND INTRODUCTION
Wolfgang Oertel, Germany
17:20 EARLY SYMPTOMS OF PARKINSON'S DISEASE: THE PATIENT'S PERSPECTIVE
Tom Isaacs, United Kingdom
17: 35 SPREADING OF PROTEIN AGGREGATES IN ANIMAL MODELS OF ALPHA-SYNUCLEINOPATHIES
Patrik Brundin, USA
17.55 ALPHA-SYNUCLEIN PATHOLOGY IN THE PERIPHERAL AND CENTRAL NERVOUS SYSTEM
Thomas Beach, USA
18.15 NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE
Brit Mollenhauer, Germany
18.35 PRODROMAL PARKINSON'S DISEASE
Ronald Postuma, Canada
18.55 NOVEL ENDPOINTS FOR MEASURING NON-MOTOR SYMPTOMS IN PD
Jamie Eberling, USA
Saturday, APRIL 1, 2017
09:15 – 11:15
Hall B
FRONTIERS IN DIAGNOSTICS AND THERAPY OF HUMAN TAUOPATHIES
Symposium Organized by: Axon Neuroscience
CHAIRS: Markus Otto, Germany, and Jonathan Rohrer, Uk
09:15 ACTIVE TAU VACCINE AADVAC1 - FROM ALZHEIMER'S DISEASE CLINICAL TRIAL TO OTHER TAUOPATHY STUDIES
Matej Ondrus ,Slovakia
09:35 THE LONGITUDINAL CHANGES IN FTD
Markus Otto, Germany
09:55 ARE WE READY FOR DISEASE MODIFYING THERAPIES OF PSP?
Günter Höglinger, Germany
10:15 DEVELOPING BIOMARKERS FOR FTD
Jonathan Rohrer,UK
10:35 MULTIMORBIDITY OF THE AGEING BRAIN; IMPLICATIONS FOR CLINICOPATHOLOGICAL CORRELATIVE STUDIES AND CLINICAL TRIALS
Johannes Attems , UK
10:55 THE COMMON TARGET FOR AD AND FTD THERAPY
Norbert Zilka ,Slovakia
17:15 – 19:15
Hall B
DLB SYMPOSIUM
Symposium Organized by: AXOVANT SCIENCES
CHAIRS: Ian McKeith, UK and James Galvin, USA
17:15 DIAGNOSIS AND MANAGEMENT OF DLB: FOURTH REPORT OF THE DLB CONSORTIUM
Ian McKeith, UK
17:30 DIFFERENTIAL DIAGNOSIS
James Galvin, USA
17:45 PHENOTYPIC VARIATION IN LEWY BODY DEMENTIA
Bradley Boeve, USA
18:00 THE ROLE OF POST-TRANSLATIONAL MODIFICATIONS ON ALPHA-SYNUCLEIN BIOLOGY AND PATHOBIOLOGY
Tiago Outeiro, Germany
18:15 CHOLINERGIC DIFFERENCES BETWEEN AD AND PD (LBD)
James Leverenz, USA
18:30 THERAPEUTICS FOR DLB
John Paul Taylor, UK
18:45 THE GENETIC BASIS OF DEMENTIA WITH LEWY BODIES
Jose Bras, UK
19:00 MODELING OF DLB AS INFORMED BY GENETIC LEADS
Michael Schlossmacher, Canada